Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Vir Bio priced public offering of 17,647,059 shares at $8.50/share, closing Feb 27, 2026.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Vir Bio priced public offering of 17,647,059 shares at $8.50/share, closing Feb 27, 2026
- Net proceeds ~$141.1M base; up to ~$162.3M if underwriters exercise full 2,647,058-share overallotment option
- Dilution risk: total potential new shares ~20.3M if greenshoe exercised fully
- Bookrunners: Goldman Sachs, Leerink Partners, Evercore, Barclays; broad syndicate signals institutional demand sought
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.